Altogether, our results uncover an important link between the MEK5/ERK5 cascade and p53-dependent apoptosis triggered by 5-FU, where ERK5-targeted inhibition arises as a promising therapeutic approach for colon cancer treatment and chemosensitization. Here, MAP2K5 is linked to malignant colon neoplasm.